AI assistant
HIKMA Pharmaceuticals PLC — Director's Dealing 2019
Mar 15, 2019
4841_dirs_2019-03-15_edafda2c-8f4c-44b3-93cb-ac25ad0cc6ce.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0300T
Hikma Pharmaceuticals Plc
15 March 2019
Notification and public disclosure of transactions by persons discharging managerial responsibilities
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mary Regina (Nina) Henderson
2
Reason for the notification
a)
Position/status
Non-executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Market purchase of 2,000 Ordinary Shares by Mary Regina (Nina) Henderson.
c)
Price(s) and volume(s)
Price(s): £15.6305
Volume(s): 2,000
d)
Aggregated information
- Volume
- Price
| 2,000 |
£31,261.00
e)
Date of the transaction
15 March 2019
f)
Place of the transaction
London Stock Exchange (XLON)
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
15 March 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHBGGDXGXBBGCU